Table 3.

Mixed models for secondary outcomes from baseline to week 5.

Outcomes			Estimate (SE; 95% CI)		P value
GAD-7a
	Intercept (AICb 591.2)	8.25 (0.94; 6.42 to 10.1)		<.001 c
	Treatment	−0.81 (1.25; −3.28 to 1.64)		.52
	Time (week 5)	−1.81 (1.05; −3.87 to 0.24)		.09
	Time (week 5)×treatment	−0.16 (1.38; −2.88 to 2.55)		.90
PHQ-9d
	Intercept (AIC 618.0)	14.17 (1.07; 12.3 to 16.5)		<.001
	Treatment	−0.88 (1.44; −3.71 to 1.94)		.54
	Time (week 5)	−3.92 (1.18; −6.23 to −1.61)		.002
	Time (week 5)×treatment	0.15 (1.56; −2.91 to 3.22)		.92
Pain Intensity NRSe
	Intercept (AIC 369.4)	7.16 (0.34; 6.50 to 7.83)		<.001
	Treatment	−0.87 (0.46; −1.76 to 0.03)		.06
	Time (week 5)	−0.42 (0.30; −1.00 to 0.16)		.16
	Time (week 5)×treatment	0.25 (0.39; −0.48 to 1.06)		.47
NPRf
	Intercept (AIC 670.7)	15.71 (1.92; 11.9 to 19.5)		<.001
	Treatment	−2.08 (2.58; −7.14 to 2.99)		.43
	Time (week 5)	−1.49 (0.95; −3.35 to 0.36)		.12
	Time (week 5)×treatment	1.51 (1.25; −0.93 to 3.96)		.23
PDIg
	Intercept (AIC 764.6)	41.30 (2.42; 36.5 to 46.1)		<.001
	Treatment	−1.43 (3.24; −7.79 to 4.93)		.66
	Time (week 5)	−2.44 (2.09; −6.53 to 1.65)		.25
	Time (week 5)×treatment	−0.85 (2.76; −6.26 to 4.56)		.76
EQ5-VASh
	Intercept (AIC 856.1)	43.33 (3.60; 36.3 to 50.4)		<.001
	Treatment	0.63 (4.84; −8.84 to 10.1)		.89
	Time (week 5)	3.13 (3.60; −3.93 to 10.2)		.39
	Time (week 5)×Treatment	3.32 (4.77; −6.02 to 12.7)		.49

^aGAD-7: Generalized Anxiety Disorder–7 items.

^bAIC: Akaike information criterion.

^cItalics indicates statistically significant results.

^dPHQ-9: Patient Health Questionnaire–9 items.

^eNRS: Numeric Rating Scale.

^fNPR: number of pain regions.

^gPDI: Pain Disability Index.

^hEQ5-VAS: European Quality of Life 5-Dimension Visual Analog Scale.